{"entity":{"id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","aka":[],"tldr":"A phase 1/2 trial of Ipilimumab, Pembrolizumab, Nivolumab in cervical cancer and colorectal cancer, run by Neonc Technologies, Inc., now recruiting.","summary":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is a phase 1/2 interventional study registered as NCT06047379 by Neonc Technologies, Inc., with 134 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-02-28. Interventions recorded: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib. Conditions listed: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06047379","url":"https://clinicaltrials.gov/study/NCT06047379"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical","colorectal","head-and-neck","melanoma","merkel-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ipilimumab","pembrolizumab","nivolumab","regorafenib","carboplatin","paclitaxel"],"companies":["neonc-technologies"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06047379","phase":"1/2","setting":"An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.","sponsor":"Neonc Technologies, Inc.","enrolled":134,"outcomes":[]},"route":"/trials/nct06047379/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"company":[{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/"}]}}